The global charcot-marie-tooth disease market is anticipated to increase as charcot-marie-tooth disease becomes more common. For instance, Charcot-Marie-Tooth disease, which affects the population and involves peripheral nerves, is the most prevalent genetic disease, according to data published by MedlinePlus in September 2020. The condition affects one in every 3,300 persons worldwide. Furthermore, according to the same publication, the PMP22 gene is mutated in 70% to 80% of CMT1 individuals. The majority of these circumstances arise when there are additional copies of the gene because of a little genetic material duplication on chromosome 17. The MPZ gene has mutations in 10% to 12% more CMT1 individuals. A mutation in the MFN2 gene, which accounts for around 20% of all instances of CMT2, is the most frequent cause of CMT2. In the GJB1 gene, 90% of CMTX patients have mutations.
Coherent Market Insights estimates that the market for Charcot-Marie-Tooth Disease will be worth US$ 793.9 million in 2021 and US$ 3,459.1 million by 2028, growing at a CAGR of 23.4% during the forecast period (2021-2028).
Key Competitors in the Charcot Marie Tooth Disease Industry:
1. Affectis Pharmaceuticals AG
The company was established in 2002 and has its headquarters in European Union. Pharmaceutical goods are discovered and created by Affectis Pharmaceuticals AG. The business sells pharmaceuticals for the management of depression, multiple sclerosis, osteoporosis, and neurological diseases.
2. Genzyme Corp
The business was founded in 1981, and its headquarters are in Cambridge, Massachusetts. Genzyme concentrates on six medical specialties, including oncology, genetics, and testing, as well as lysosomal storage illnesses, renal illness, orthopaedics, transplantation and immunological illnesses.
3. Acceleron Pharma
The business was founded in June 2003 and has its headquarters in Cambridge, Massachusetts. the business's efforts are directed towards creating drugs that control the TGF- superfamily of proteins, which is essential for the growth and repair of various cells and tissues, including red blood cells, muscle, bone, and blood vessels. This year's largest biopharma deal was given by Acceleron, who will sell $11.5 billion to Merck in September 2021. The outcomes of a Phase III trial examining sotatercept were released by Merck & Co. in October 2022.
4. Pharnext SA
The business was established in 2007 and has its main office in Paris, France. Pharnext SA conducts research and produces biopharmaceutical goods. The business creates pharmaceuticals and therapies for neurological conditions such down syndrome, multiple sclerosis, parkinson's, and Alzheimer's. Pharnext reports that the transfer of manufacturing and scaling up of PXT3003 in the United States were successful and were completed on January 25, 2023. The debt refinancing and new loan contract announced by Pharnext on June 7th, 2022
5. MedDay Pharmaceuticals
The business was established in 2011and has its main office in Paris, France A biotechnology firm called MedDay is creating new medications that target the metabolism of the brain. In March 2020, MedDay published Top-Line Results from the Phase III Study "SPI2" for the Treatment of Progressive Forms of Multiple Sclerosis.
6. Bristol-Myers-Squibb Company
The Squibb Corporation was established in 1858 and has its corporate headquarters in New York City. The medical conditions for which Bristol Myers Squibb produces prescription medications and biologics. Anteros Pharmaceuticals, a new business founded in February 2020 by BMS and collaborator Biomotiv, focuses on developing anti-inflammation and anti-fibrosis drugs. On January 27th, 2023, Bristol Myers Squibb announced that once-daily Sotyktu (deucravacitinib) has received a favourable CHMP opinion for treating adults with moderate-to-severe plaque psoriasis.
7. Inflectis Bio Science Health Company
The company was founded in 2013 and has its main office in Nantes, Pays de la Loire, France. To treat illnesses caused by misfolding proteins, the company creates small molecule medications that target the unfolded protein response. In December 2022, InFlectis BioScience administered IFB-088 to the first patient in a phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis.
8. Helixmith Co., Ltd.
Helixmith Co. LTD., based in Seoul, South Korea, was founded in 1996. Helixmith Co., Ltd. develops and sells bio and natural chemicals, as well as produces innovative medications and medical products. In November 2021, Helixmith Co. Ltd. released encouraging topline results from the first gene therapy phase 1 study ever conducted for CMT. In September 2022, Helixmith announced the topline findings from the Phase 2A trial of Engensis for the therapy of ALS.
Definition: Charcot-Marie- One of the conditions that harms the peripheral nerves, which carry information and signals from the brain and spinal cord to and from the rest of the body, is tooth disease (CMT).
